T
Tom H. M. Ottenhoff
Researcher at Leiden University Medical Center
Publications - 465
Citations - 30196
Tom H. M. Ottenhoff is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Tuberculosis & Mycobacterium tuberculosis. The author has an hindex of 91, co-authored 428 publications receiving 27095 citations. Previous affiliations of Tom H. M. Ottenhoff include Leiden University & Loyola University Medical Center.
Papers
More filters
Journal ArticleDOI
Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria
Frank A. W. Verreck,Tjitske de Boer,Dennis M. L. Langenberg,Marieke A. Hoeve,Matthijs Kramer,Elena Vaisberg,Robert A. Kastelein,Arend J. Kolk,Rene de Waal-Malefyt,Tom H. M. Ottenhoff +9 more
TL;DR: IL-23 rather than IL-12 is the primary type 1 cytokine produced by activated proinflammatory Mphi-1, indicating that Mphi heterogeneity thus may be an important determinant of immunity and disease outcome in intracellular bacterial infection.
Journal ArticleDOI
Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient Patients
Rolien de Jong,Frédéric Altare,Inez-Anne Haagen,Diënne G. Elferink,Tjitske de Boer,Peter J. C. van Breda Vriesman,Peter J. Kabel,Johannes M. T. Draaisma,Jaap T. van Dissel,Frank P. Kroon,Jean-Laurent Casanova,Tom H. M. Ottenhoff +11 more
TL;DR: The lack of IL-12Rbeta1 expression results in a human immunodeficiency and shows the essential role in resistance to infections due to intracellular bacteria.
Journal ArticleDOI
Innate Immunity to Mycobacterium tuberculosis
TL;DR: Different natural effector mechanisms for killing of M. tuberculosis have now been identified and these basic mechanisms augment the understanding of disease pathogenesis and clinical course and will be of help in designing adjunctive treatment strategies.
Journal ArticleDOI
A blood RNA signature for tuberculosis disease risk: a prospective cohort study.
Daniel E. Zak,Adam Penn-Nicholson,Thomas J. Scriba,Ethan G. Thompson,Sara Suliman,Lynn M. Amon,Hassan Mahomed,Mzwandile Erasmus,Wendy Whatney,Gregory D. Hussey,Deborah Abrahams,Fazlin Kafaar,Tony Hawkridge,Suzanne Verver,E. Jane Hughes,Martin O. C. Ota,Jayne S. Sutherland,Rawleigh Howe,Hazel M. Dockrell,W. Henry Boom,Bonnie Thiel,Tom H. M. Ottenhoff,Harriet Mayanja-Kizza,Amelia C. Crampin,Katrina Downing,Mark Hatherill,Joe Valvo,Smitha Shankar,Shreemanta K. Parida,Stefan H. E. Kaufmann,Gerhard Walzl,Alan Aderem,Willem A. Hanekom +32 more
TL;DR: The whole blood tuberculosis risk signature prospectively identified people at risk of developing active tuberculosis, opening the possibility for targeted intervention to prevent the disease.
Journal ArticleDOI
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.
Mary E. Morgan,Jolanda H. M. van Bilsen,A Bakker,Bianca Heemskerk,Marco W. Schilham,Franca C. Hartgers,B. G. Elferink,Linda van der Zanden,René R. P. de Vries,Tom W J Huizinga,Tom H. M. Ottenhoff,René E. M. Toes +11 more
TL;DR: The results indicate that FOXP3 expression in humans, unlike mice, may not be specific for cells with a regulatory phenotype and may be only a consequence of activation status.